BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Normington C, Moura IB, Bryant JA, Ewin DJ, Clark EV, Kettle MJ, Harris HC, Spittal W, Davis G, Henn MR, Ford CB, Wilcox MH, Buckley AM. Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection. NPJ Biofilms Microbiomes 2021;7:16. [PMID: 33547298 DOI: 10.1038/s41522-021-00184-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang J, Meng L, Yang H. Therapeutic Effects of Bifidobacterium breve YH68 in Combination with Vancomycin and Metronidazole in a Primary Clostridioides difficile-Infected Mouse Model. Microbiol Spectr 2022;10:e0067222. [PMID: 35311540 DOI: 10.1128/spectrum.00672-22] [Reference Citation Analysis]
2 Rahmoun LA, Azrad M, Peretz A. Antibiotic Resistance and Biofilm Production Capacity in Clostridioides difficile. Front Cell Infect Microbiol 2021;11:683464. [PMID: 34422678 DOI: 10.3389/fcimb.2021.683464] [Reference Citation Analysis]
3 Wang PW, Lee WT, Wu YN, Shieh DB. Opportunities for Nanomedicine in Clostridioides difficile Infection. Antibiotics (Basel) 2021;10:948. [PMID: 34438998 DOI: 10.3390/antibiotics10080948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Brauer M, Lassek C, Hinze C, Hoyer J, Becher D, Jahn D, Sievers S, Riedel K. What's a Biofilm?-How the Choice of the Biofilm Model Impacts the Protein Inventory of Clostridioides difficile. Front Microbiol 2021;12:682111. [PMID: 34177868 DOI: 10.3389/fmicb.2021.682111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Meza-Torres J, Auria E, Dupuy B, Tremblay YDN. Wolf in Sheep's Clothing: Clostridioides difficile Biofilm as a Reservoir for Recurrent Infections. Microorganisms 2021;9:1922. [PMID: 34576818 DOI: 10.3390/microorganisms9091922] [Reference Citation Analysis]
6 Buckley AM, Moura IB, Wilcox MH. The potential of microbiome replacement therapies for Clostridium difficile infection. Curr Opin Gastroenterol 2022;38:1-6. [PMID: 34871192 DOI: 10.1097/MOG.0000000000000800] [Reference Citation Analysis]
7 Tremblay YD, Dupuy B. The blueprint for building a biofilm the Clostridioides difficile way. Curr Opin Microbiol 2021;66:39-45. [PMID: 34933207 DOI: 10.1016/j.mib.2021.12.002] [Reference Citation Analysis]
8 Brauer M, Herrmann J, Zühlke D, Müller R, Riedel K, Sievers S. Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis. Gut Pathog 2022;14:4. [PMID: 34991700 DOI: 10.1186/s13099-021-00475-9] [Reference Citation Analysis]
9 Taggart MG, Snelling WJ, Naughton PJ, La Ragione RM, Dooley JSG, Ternan NG. Biofilm regulation in Clostridioides difficile: Novel systems linked to hypervirulence. PLoS Pathog 2021;17:e1009817. [PMID: 34499698 DOI: 10.1371/journal.ppat.1009817] [Reference Citation Analysis]
10 Tomkovich S, Taylor A, King J, Colovas J, Bishop L, McBride K, Royzenblat S, Lesniak NA, Bergin IL, Schloss PD. An Osmotic Laxative Renders Mice Susceptible to Prolonged Clostridioides difficile Colonization and Hinders Clearance. mSphere 2021;6:e0062921. [PMID: 34585964 DOI: 10.1128/mSphere.00629-21] [Reference Citation Analysis]
11 Monaghan TM, Seekatz AM, Mullish BH, Moore-Gillon CCER, Dawson LF, Ahmed A, Kao D, Chan WC. Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opin Ther Targets 2021;:1-15. [PMID: 34793686 DOI: 10.1080/14728222.2021.2008907] [Reference Citation Analysis]